Actuate Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ACTU Nasdaq 2834 actuatetherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Actuate Therapeutics, Inc.

Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial - Jun 24th, 2025 7:15 am
Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO - Jun 20th, 2025 6:45 am
Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes - Jun 16th, 2025 6:30 am
Actuate Therapeutics shares highlights from KOL eventon elraglusib data - Jun 3rd, 2025 7:15 am
Actuate Therapeutics Shares Highlights from KOL Event on Positive Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer - Jun 2nd, 2025 7:00 am
Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer - May 31st, 2025 2:30 pm
Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer - May 22nd, 2025 3:05 pm
Actuate Therapeutics to Host KOL Event on Topline Phase 2 Data of Elraglusib in Metastatic Pancreatic Ductal Adenocarcinoma During ASCO Annual Meeting - May 7th, 2025 6:00 am
Actuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic Cancer - May 6th, 2025 6:00 am
Actuate Therapeutics to Participate in Citizens Life Sciences Conference 2025 - Apr 30th, 2025 6:00 am
Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - Apr 23rd, 2025 8:24 am
Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025 - Apr 17th, 2025 6:00 am
Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer - Feb 25th, 2025 6:00 am
Is Actuate Therapeutics (NASDAQ:ACTU) In A Good Position To Deliver On Growth Plans? - Feb 12th, 2025 3:55 am
Actuate Therapeutics to Participate in Upcoming Investor Conferences in February - Feb 6th, 2025 6:00 am
Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer - Jan 7th, 2025 6:00 am
Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer - Dec 17th, 2024 6:28 am
Actuate Therapeutics to be Added to Russell 2000® Index - Nov 26th, 2024 6:00 am
Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma - Nov 12th, 2024 6:00 am
Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development - Oct 29th, 2024 4:39 pm